My NCBISign In

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 167

    1.

    Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: Study of immunological memory and long-term toxicology.

    Bråve A, Gudmundsdotter L, Gasteiger G, Hallermalm K, Kastenmuller W, Rollman E, Boberg A, Engström G, Reiland S, Cosma A, Drexler I, Hinkula J, Wahren B, Erfle V.

    Infect Agent Cancer. 2007 Jul 10;2:14.PMID: 17623060 [PubMed - in process]Related articlesFree article

    2.

    Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.

    Garber DA, O'Mara LA, Zhao J, Gangadhara S, An I, Feinberg MB.

    PLoS One. 2009;4(5):e5445. Epub 2009 May 6.PMID: 19421328 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice.

    Bråve A, Boberg A, Gudmundsdotter L, Rollman E, Hallermalm K, Ljungberg K, Blomberg P, Stout R, Paulie S, Sandström E, Biberfeld G, Earl P, Moss B, Cox JH, Wahren B.

    Mol Ther. 2007 Sep;15(9):1724-33. Epub 2007 Jun 19.PMID: 17579577 [PubMed - indexed for MEDLINE]Related articles

    4.

    A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.

    Shephard E, Burgers WA, Van Harmelen JH, Monroe JE, Greenhalgh T, Williamson C, Williamson AL.

    AIDS Res Hum Retroviruses. 2008 Feb;24(2):207-17.PMID: 18240963 [PubMed - indexed for MEDLINE]Related articles

    5.

    Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.

    Gómez CE, Nájera JL, Jiménez V, Bieler K, Wild J, Kostic L, Heidari S, Chen M, Frachette MJ, Pantaleo G, Wolf H, Liljeström P, Wagner R, Esteban M.

    Vaccine. 2007 Mar 1;25(11):1969-92. Epub 2006 Dec 6.PMID: 17224219 [PubMed - indexed for MEDLINE]Related articles

    6.

    Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons.

    Burgers WA, Chege GK, Müller TL, van Harmelen JH, Khoury G, Shephard EG, Gray CM, Williamson C, Williamson AL.

    J Gen Virol. 2009 Feb;90(Pt 2):468-80.PMID: 19141458 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals.

    Cosma A, Nagaraj R, Bühler S, Hinkula J, Busch DH, Sutter G, Goebel FD, Erfle V.

    Vaccine. 2003 Dec 8;22(1):21-9.PMID: 14604567 [PubMed - indexed for MEDLINE]Related articles

    8.

    Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.

    Blazevic V, Männik A, Malm M, Sikut R, Valtavaara M, Toots U, Ustav M, Krohn K.

    AIDS Res Hum Retroviruses. 2006 Jul;22(7):667-77.PMID: 16831091 [PubMed - indexed for MEDLINE]Related articles

    10.

    Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.

    Gómez CE, Nájera JL, Jiménez EP, Jiménez V, Wagner R, Graf M, Frachette MJ, Liljeström P, Pantaleo G, Esteban M.

    Vaccine. 2007 Apr 12;25(15):2863-85. Epub 2006 Oct 16.PMID: 17113200 [PubMed - indexed for MEDLINE]Related articles

    11.

    Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'.

    Chen Z, Huang Y, Zhao X, Ba L, Zhang W, Ho DD.

    J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):412-21.PMID: 18209682 [PubMed - indexed for MEDLINE]Related articles

    12.

    Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination.

    Koopman G, Mortier D, Hofman S, Mathy N, Koutsoukos M, Ertl P, Overend P, van Wely C, Thomsen LL, Wahren B, Voss G, Heeney JL.

    J Gen Virol. 2008 Feb;89(Pt 2):540-53.PMID: 18198386 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

    Gahéry-Ségard H, Pialoux G, Figueiredo S, Igéa C, Surenaud M, Gaston J, Gras-Masse H, Lévy JP, Guillet JG.

    J Virol. 2003 Oct;77(20):11220-31.PMID: 14512570 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter.

    Cazeaux N, Bennasser Y, Vidal PL, Li Z, Paulin D, Bahraoui E.

    Vaccine. 2002 Sep 10;20(27-28):3322-31.PMID: 12213402 [PubMed - indexed for MEDLINE]Related articles

    15.

    Characterization of humoral and cellular immune responses in mice induced by immunization with HIV-1 Nef regulatory protein encapsulated in poly(DL-lactide-co-glycolide) microparticles.

    Moureau C, Vidal PL, Bennasser Y, Moynier M, Nicaise Y, Aussillous M, Barthelemy S, Montagnier L, Bahraoui E.

    Mol Immunol. 2002 Jan;38(8):607-18.PMID: 11792429 [PubMed - indexed for MEDLINE]Related articles

    16.

    Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.

    Yu S, Feng X, Shu T, Matano T, Hasegawa M, Wang X, Ma H, Li H, Li Z, Zeng Y.

    Vaccine. 2008 Nov 11;26(48):6124-31. Epub 2008 Sep 22.PMID: 18812199 [PubMed - indexed for MEDLINE]Related articles

    17.

    Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine.

    Hanke T, Barnfield C, Wee EG, Agren L, Samuel RV, Larke N, Liljeström P.

    J Gen Virol. 2003 Feb;84(Pt 2):361-8.PMID: 12560568 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen.

    Alekseeva E, Sominskaya I, Skrastina D, Egorova I, Starodubova E, Kushners E, Mihailova M, Petrakova N, Bruvere R, Kozlovskaya T, Isaguliants M, Pumpens P.

    Genet Vaccines Ther. 2009 Jun 8;7:7.PMID: 19505299 [PubMed - in process]Related articlesFree article

    19.

    Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.

    Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC, Hill AV.

    J Immunol. 2005 Jan 1;174(1):449-55.PMID: 15611270 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C.

    Burgers WA, Shephard E, Monroe JE, Greenhalgh T, Binder A, Hurter E, Van Harmelen JH, Williamson C, Williamson AL.

    AIDS Res Hum Retroviruses. 2008 Feb;24(2):195-206.PMID: 18240957 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination
    Write to the Help Desk